IRIDEX Corporation

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 27, 2026, IRIDEX Corporation (the “Company”) received a notification of non-compliance (the “Notice”) from Nasdaq’s Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days from receipt of the Notice, or until February 23, 2027, to regain compliance with the Minimum Bid Price Requirement (the “Cure Period”). The Company will regain compliance if the closing bid price of its common stock is at least $1.00 per share for a minimum of ten consecutive business days during the Cure Period, after which the Staff would provide written confirmation of compliance and the matter would be closed. In the event the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the Cure Period, the Company may be eligible for additional time to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, the Company will be granted an additional 180 calendar days to regain compliance. If the Company does not qualify for or fails to regain compliance during the second compliance period, then the Nasdaq staff will provide written notification to the Company that its common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. The Notice has no immediate impact on the listing of the Company’s common stock and will continue to be listed and traded on Nasdaq during the Cure Period, subject to Nasdaq’s confirmation of regained compliance and the Company’s continued compliance with Nasdaq’s other continued listing requirements. The current noncompliance with the Nasdaq listing requirements does not affect the Company’s ongoing business operations or its SEC reporting requirements. The Company intends to actively monitor the closing bid price of its common stock and is considering all available options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the Cure Period, secure an extension of the compliance period beyond the Cure Period or maintain compliance with any other Nasdaq listing requirements.